Mizuho reissued their hold rating on shares of Adamas Pharmaceuticals (NASDAQ:ADMS) in a research note published on Friday morning. They currently have a $11.00 price objective on the specialty pharmaceutical company’s stock.
“We see minimal 2019 catalysts or take-out possibility for Adamas, and reiterate our Neutral rating. We also believe the stock will be pressured by the recent launch of Osmolex ER. We updated our model following guidance on 2019 Gocovri growth and a 7.75% price increase, with no change to our $11 PT.”,” Mizuho’s analyst wrote.
Other analysts have also recently issued reports about the company. Cowen set a $30.00 price objective on Adamas Pharmaceuticals and gave the company a buy rating in a research report on Thursday, November 1st. HC Wainwright restated a buy rating and issued a $40.00 price objective on shares of Adamas Pharmaceuticals in a research report on Monday, November 5th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, November 6th. ValuEngine cut Adamas Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, November 2nd. Finally, Bank of America cut Adamas Pharmaceuticals from a buy rating to a neutral rating and dropped their price target for the stock from $36.00 to $25.00 in a research report on Friday, October 5th. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $31.25.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported ($1.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.34) by $0.12. The business had revenue of $10.61 million during the quarter, compared to analysts’ expectations of $10.10 million. Adamas Pharmaceuticals had a negative return on equity of 106.74% and a negative net margin of 617.27%. On average, equities research analysts anticipate that Adamas Pharmaceuticals will post -5.22 EPS for the current fiscal year.
In other news, CEO Gregory T. Went purchased 3,850 shares of the company’s stock in a transaction that occurred on Wednesday, November 7th. The stock was purchased at an average cost of $12.98 per share, for a total transaction of $49,973.00. Following the completion of the transaction, the chief executive officer now owns 182,610 shares of the company’s stock, valued at $2,370,277.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 24.60% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of ADMS. Rhumbline Advisers grew its holdings in Adamas Pharmaceuticals by 36.0% in the 2nd quarter. Rhumbline Advisers now owns 20,892 shares of the specialty pharmaceutical company’s stock valued at $540,000 after buying an additional 5,525 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Adamas Pharmaceuticals by 12.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 246,352 shares of the specialty pharmaceutical company’s stock valued at $6,363,000 after purchasing an additional 27,696 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of Adamas Pharmaceuticals by 37.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 48,857 shares of the specialty pharmaceutical company’s stock valued at $1,262,000 after purchasing an additional 13,367 shares during the last quarter. Swiss National Bank acquired a new position in shares of Adamas Pharmaceuticals in the 2nd quarter valued at $966,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Adamas Pharmaceuticals in the 2nd quarter valued at $212,000. Institutional investors own 94.01% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Featured Article: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.